Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care successfully raises EUR 100 million via issuance of floating rate senior notes
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Bond
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care
successfully raises EUR 100 million via issuance of floating rate
senior notes
10.10.2011 / 12:57
---------------------------------------------------------------------
Contact: Fresenius Medical Care AG & Co. KGaA
Oliver Maier Else-Kröner-Str.1
Phone: + 49 6172 609 2601 61352 Bad Homburg
Fax: + 49 6172 609 2301 Germany
www.fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com October 10, 2011
Investor News
Fresenius Medical Care successfully raises EUR 100 million via issuance of
floating rate senior notes
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA ('the Company'
or 'Fresenius Medical Care'; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, today announced the pricing of euro-denominated floating-rate
senior notes ('Senior Notes'). The aggregate principal amount to be issued
is EUR100 million.
The Senior Notes will be issued at par and carry interest of three-month
Euribor plus 350 basis points. The Senior Notes will mature on October 15,
2016. The Senior Notes will be offered by FMC Finance VIII S.A., a
wholly-owned subsidiary of the Company, in a private placement outside the
United States to non-US institutional investors only. The Senior Notes will
be guaranteed jointly and severally by the Company and its subsidiaries,
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care
Deutschland GmbH. The Company expects to close and settle the offering on
October 17, 2011, subject to customary closing conditions.
Michael Brosnan, chief financial officer of the Company, commented: 'We
will take advantage of the additional market demand in excess of our
recently issued fixed rate senior notes. We will use the proceeds to repay
debt and for other corporate purposes'.
The Senior Notes will not be registered under the Securities Act of 1933 as
amended, and will be offered in exempted 'offshore transactions' pursuant
to Regulation S under the Securities Act. The Senior Notes may not be
offered or sold in the U.S. unless registered under the Securities Act or
pursuant to an applicable exemption from registration requirements.
***************
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2 million
individuals worldwide. Through its network of 2,838 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 225,909 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
This release does not constitute or form part of, and should not be
construed as, an offer or invitation to subscribe for, underwrite or
otherwise acquire, any securities of FMC Finance VIII S.A., or Fresenius
Medical Care or any present or future member of its group nor should it or
any part of it form the basis of, or be relied on in connection with, any
contract to purchase or subscribe for any securities of FMC Finance VIII
S.A. or Fresenius Medical Care or any member of its group. In particular,
this release is not an offer to sell or a solicitation of offers to
purchase any securities in the United States of America (including its
territories and possessions), and securities of FMC Finance VIII S.A. and
Fresenius Medical Care may not be offered or sold in the United States of
America or to United States persons absent registration under the
Securities Act of 1933, as amended, (which FMC Finance VIII S.A. and
Fresenius Medical Care do not intend to effect) or pursuant to an
applicable exemption from registration.
The information contained in this release may not be issued or distributed
in or into Canada, Australia or Japan and does not constitute an offer to
sell nor an invitation to subscribe for, underwrite or otherwise acquire
securities in Canada, Australia or Japan.
End of Corporate News
---------------------------------------------------------------------
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
End of News DGAP News-Service
---------------------------------------------------------------------
141791 10.10.2011
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Bond
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care
successfully raises EUR 100 million via issuance of floating rate
senior notes
10.10.2011 / 12:57
---------------------------------------------------------------------
Contact: Fresenius Medical Care AG & Co. KGaA
Oliver Maier Else-Kröner-Str.1
Phone: + 49 6172 609 2601 61352 Bad Homburg
Fax: + 49 6172 609 2301 Germany
www.fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com October 10, 2011
Investor News
Fresenius Medical Care successfully raises EUR 100 million via issuance of
floating rate senior notes
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA ('the Company'
or 'Fresenius Medical Care'; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, today announced the pricing of euro-denominated floating-rate
senior notes ('Senior Notes'). The aggregate principal amount to be issued
is EUR100 million.
The Senior Notes will be issued at par and carry interest of three-month
Euribor plus 350 basis points. The Senior Notes will mature on October 15,
2016. The Senior Notes will be offered by FMC Finance VIII S.A., a
wholly-owned subsidiary of the Company, in a private placement outside the
United States to non-US institutional investors only. The Senior Notes will
be guaranteed jointly and severally by the Company and its subsidiaries,
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care
Deutschland GmbH. The Company expects to close and settle the offering on
October 17, 2011, subject to customary closing conditions.
Michael Brosnan, chief financial officer of the Company, commented: 'We
will take advantage of the additional market demand in excess of our
recently issued fixed rate senior notes. We will use the proceeds to repay
debt and for other corporate purposes'.
The Senior Notes will not be registered under the Securities Act of 1933 as
amended, and will be offered in exempted 'offshore transactions' pursuant
to Regulation S under the Securities Act. The Senior Notes may not be
offered or sold in the U.S. unless registered under the Securities Act or
pursuant to an applicable exemption from registration requirements.
***************
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2 million
individuals worldwide. Through its network of 2,838 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 225,909 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
This release does not constitute or form part of, and should not be
construed as, an offer or invitation to subscribe for, underwrite or
otherwise acquire, any securities of FMC Finance VIII S.A., or Fresenius
Medical Care or any present or future member of its group nor should it or
any part of it form the basis of, or be relied on in connection with, any
contract to purchase or subscribe for any securities of FMC Finance VIII
S.A. or Fresenius Medical Care or any member of its group. In particular,
this release is not an offer to sell or a solicitation of offers to
purchase any securities in the United States of America (including its
territories and possessions), and securities of FMC Finance VIII S.A. and
Fresenius Medical Care may not be offered or sold in the United States of
America or to United States persons absent registration under the
Securities Act of 1933, as amended, (which FMC Finance VIII S.A. and
Fresenius Medical Care do not intend to effect) or pursuant to an
applicable exemption from registration.
The information contained in this release may not be issued or distributed
in or into Canada, Australia or Japan and does not constitute an offer to
sell nor an invitation to subscribe for, underwrite or otherwise acquire
securities in Canada, Australia or Japan.
End of Corporate News
---------------------------------------------------------------------
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
End of News DGAP News-Service
---------------------------------------------------------------------
141791 10.10.2011